Dementia Drugs Market

Dementia is the term used to describe the symptoms of a large group of illnesses that cause a progressive decline in a persons functioning.

It is a broad term to describe a loss of memory, intellect, rationality, social skills and what would be considered normal emotional reactions. Dementia causes significant impairment in a persons day to day functioning.

There are no drug treatments that can cure Alzheimers disease or any other common type of dementia. However, there are medicines for Alzheimers disease that can ease symptoms for a while, or slow down their progression, in some people. These drugs do not slow down or stop the progression of the underlying disease in the brain.

Dementia Drugs Market focus on Dementia Drugs market.

Dementia Drugs Market contains market size and forecasts of Dementia Drugs in global, including the following market information:

Global Dementia Drugs Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global Dementia Drugs Market Sales, 2017-2022, 2023-2028, (K Units)

Global top five Dementia Drugs companies in 2021 (%)

The global Dementia Drugs market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

MAO Inhibitors Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Dementia Drugs include Eisai, Inc, Janssen Pharmaceuticals, Inc, Biogen Pharmaceuticals, Forest Laboratories, Inc, Eli Lilly and Company, Novartis AG, Sanofi S.A, AstraZeneca GmbH and F. Hoffmann-La Roche, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

We surveyed the Dementia Drugs manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Dementia Drugs Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global Dementia Drugs Market Segment Percentages, by Type, 2021 (%)

• MAO Inhibitors
• Cholinesterase Inhibitors
• Glutamate Inhibitors

Global Dementia Drugs Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global Dementia Drugs Market Segment Percentages, by Application, 2021 (%)

• Hospital Pharmacies
• Retail Pharmacies
• Others

Global Dementia Drugs Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global Dementia Drugs Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

• Key companies Dementia Drugs revenues in global market, 2017-2022 (Estimated), ($ millions)
• Key companies Dementia Drugs revenues share in global market, 2021 (%)
• Key companies Dementia Drugs sales in global market, 2017-2022 (Estimated), (K Units)
• Key companies Dementia Drugs sales share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Eisai, Inc
• Janssen Pharmaceuticals, Inc
• Biogen Pharmaceuticals
• Forest Laboratories, Inc
• Eli Lilly and Company
• Novartis AG
• Sanofi S.A
• AstraZeneca GmbH
• F. Hoffmann-La Roche
• Merck & Co., Inc
• Valeant Pharmaceutical International
• Pfizer Inc
• Teva Pharmaceuticals Industries